Incidência da fibrose pulmonar desenvolvida em idosos pós-contaminação da COVID-19 - revisão narrativa
DOI:
https://doi.org/10.34117/bjdv9n8-096Keywords:
fibrose pulmonar, COVID-19, função respiratória, idosoAbstract
Introdução: A Fibrose Pulmonar (FP) é uma patologia decorrente de deposições resistentes de matriz extracelular no interstício dos pulmões, associado à danificação do parênquima pulmonar que resulta em um déficit progressivo da função respiratória. Quando decorrente da COVID-19, é caracterizada por cicatrizes permanentes nos pulmões, podendo resultar na perda da capacidade funcional pulmonar. Foi identificada com maior frequência em indivíduos idosos, com idade média de 65 anos, o que torna este grupo mais propenso à manifestação de sintomas mais graves. Objetivo: Verificar na literatura a ocorrência dos mecanismos da Fibrose Pulmonar decorrente da COVID-19 na população idosa. Metodologia: Refere-se a uma revisão narrativa por levantamento bibliográfico em bancos de dados, incluindo artigos em inglês e português publicados entre 2017 e 2022, foram selecionados 37 artigos. Considerações finais: A FP tem sido desenvolvida de maneira frequente em pacientes contaminados pela COVID-19, tem predominância em indivíduos idosos devido à senescência, pois este grupo já apresenta alterações naturais no modelamento e capacidade pulmonar, fator que estimula a diminuição de fibroblastos no parênquima pulmonar, o que pode gerar um pior prognóstico a esses indivíduos.
References
ADHIKARI, S. P. et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scop ing review. Infectious diseases of poverty, v. 9, n. 1, p. 1-12, 2020.
BRIDI, G. Fibrose pulmonar secundária à Covid-19. PEBMED, Brasil, 2021.
COTTIN, V. et al. Fibrosing interstitial lung diseases: knowns and unknowns. European Respiratory Review, v. 28, n. 151, 2019.
D'ETTORRE, G. et al. Covid‐19 sequelae in working age patients: A systematic review.
Journal of Medical Virology, v. 94, n. 3, p. 858-868, 2022.
GEORGE, P. M.; WELLS, A. U.; JENKINGS, R. G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. The Lancet Respiratory Medicine, v. 8, n. 8, p. 807- 815, 2020.
JOHN, A. E. et al. COVID‐19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts. Immunological Reviews, v. 302, n. 1, p. 228-240, 2021.
JUDSON, M. A. Strategies for identifying pulmonary sarcoidosis patients at risk for severe or chronic disease. Expert Review of Respiratory Medicine, v. 11, n. 2, p. 111-118, 2017.
KAMAL, M. et al. Assessment and characterisation of post‐COVID‐19 manifestations. International journal of clinical practice, v. 75, n. 3, p. e13746, 2021.
LECHOWICZ, K. et al. COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection. Journal of clinical medicine, v. 9, 2020.
LEDERER, D. J..; MARTINEZ, F. J. Idiopathic pulmonary fibrosis. New England Journal of Medicine, v. 378, n. 19, p. 1811-1823, 2018.
LI, Y. et al. Progression to fibrosing diffuse alveolar damage in a series of 30 minimally invasive autopsies with COVID‐19 pneumonia in Wuhan, China. Histopathology, v. 78, n. 4, p. 542-555, 2021.
LIU, X. et al. Risk factors associated with disease severity and length of hospital stay in COVID-19 patients. Journal of Infection, v. 81, n. 1, p. e95-e97, 2020.
LYNCH, D. A. et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. The Lancet respiratory medicine, v. 6, n. 2, p. 138-153, 2018.
MARTINEZ, F. J. et al. Idiopathic pulmonary fibrosis. Nature reviews Disease primers, v. 3, n. 1, p. 1-19, 2017.
OTOUPALOVA, E. et al. Oxidative Stress in Pulmonary Fibrosis. Compr Physiol, 2020.
PARDO, A; SELMAN, M. The interplay of the genetic architecture, aging, and environmental factors in the pathogenesis of idiopathic pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Biology, v. 64, n. 2, p. 163-172, 2021.
PODOLANCZUK, A. J. et al. Update in Interstitial Lung Disease 2020. American journal of Respiratory and Critical Care Medicine, v. 203, p. 1343-1352, 2021.
RAGHU, G. et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. American journal of respiratory and critical care medicine, v. 198, n. 5, p. e44-e68, 2018.
RAI, D; SHARMA, P; KUMAR, R. Post covid-19 pulmonary fibrosis. Is it real threat?. Indian Journal of Tuberculosis, v. 68, n. 3, p. 330-333, 2021.
RANUCCI, M. et al. The procoagulant pattern of patients with COVID‐19 acute respiratory distress syndrome. Journal of Thrombosis and Haemostasis, v. 18, n. 7, p. 1747-1751, 2020.
RICHELDI, L.; COLLARD, H. R.; JONES. M. G. Idiopathic pulmonary fibrosis. The Lancet, v. 389, n. 10082, p. 1941-1952, 2017.
RODRIGUEZ, G. C. Clinical features and treatment of Langerhans cell histiocytosis. Acta Paediatrica, v. 110, n. 11, p. 2892-2902, 2021.
SANTANA, A. V.; FONTANA, A. D.; PITTA, F. Pulmonary rehabilitation after COVID-
Jornal Brasileiro de Pneumologia, v. 47, 2021.
SETHURAMAN, N.; JEREMIAH, S. S.; RYO, A. Interpreting diagnostic tests for SARS- CoV-2. Jama. v. 323, n. 22, p. 2249-2251, 2020.
SGALLA, G. et al. Idiopathic pulmonary fibrosis: pathogenesis and management. Respiratory research, v. 19, n. 1, p. 1-18, 2018.
SPRUIT, M. A. et al. COVID-19: interim guidance on rehabilitation in the hospital and post- hospital phase from a European Respiratory Society-and American Thoracic Society- coordinated international task force. European respiratory journal, v. 56, n. 6, 2020.
SUNDARAKRISHNAN, A. et al. Engineered cell and tissue models of pulmonary fibrosis.
Advanced Drug Delivery Reviews, v. 129, p. 78-94, 2018.
SUN, X. et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine & growth factor reviews, v. 53, p. 38-42, 2020.
TANNI, S. E. et al. Pulmonary fibrosis secondary to COVID-19: a narrative review. Expert review of respiratory medicine, v. 15, n. 6, p. 791-803, 2021.
UHLER, C.; SHIVASHANKAR, G. V. Regulation of genome organization and gene expression by nuclear mechanotransduction. Nature reviews Molecular cell biology, v. 18, n. 12, p. 717-727, 2017.
UHLER, C.; SHIVASHANKAR, G. V. Mechano-genomic regulation of coronaviruses and its interplay with ageing. Nature Reviews Molecular Cell Biology, v. 21, n. 5, p. 247-248, 2020.
WESSELS, I; ROLLES, B; RINK, L. The potential impact of zinc supplementation on COVID-19 pathogenesis. Frontiers in immunology, p. 1712, 2020.
WILLI, S. et al. COVID-19 sequelae in adults aged less than 50 years: a systematic re- view. Travel medicine and infectious disease, v. 40, p. 101995, 2021.
WORLD HEALTH ORGANIZATION (WHO). Director-General's opening remarks at the media briefing on COVID-19. 11 March, 2020.
WU, Z; MCGOOGAN, J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama, v. 323, n. 13, p. 1239-1242, 2020.
XUE, M. et al. Krebs Von den Lungen-6 as a predictive indicator for the risk of secondary pulmonary fibrosis and its reversibility in COVID-19 patients. International journal of biological sciences, v. 17, n. 6, p. 1565, 2021.
YU, M. et al. Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia. Korean journal of radiology, v. 21, n. 6, p. 746, 2020.
